Literature DB >> 325009

Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations.

E D Cooke, M H Dawson, R M Ibbotson, S A Bowcock, M E Ainsworth, M F Pilcher.   

Abstract

In a double-blind, randomized trial of orally administered hydroxychloroquine sulphate in the prevention of venous thromboembolism after elective surgery on the hip, the drug or a placebo was given to fifty consecutive patients. Therapy was commenced on the day before the operation and continued for fourteen days. The diagnosis of deep venous thrombosis was made by daily thermographic scanning of the legs and confirmed by phlebography. The diagnosis of pulmonary embolism was made by perfusion lung scanning. No significant difference in the incidence of thromboembolism was found between treated and control groups. The results provide evidence that substances which reduce the incidence of thromboembolism in general surgery may not be effective in operations on the hip.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 325009

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  7 in total

Review 1.  Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients.

Authors:  Michelle Petri
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 2.  The non-haemostatic role of platelets in systemic lupus erythematosus.

Authors:  Petrus Linge; Paul R Fortin; Christian Lood; Anders A Bengtsson; Eric Boilard
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

3.  Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-22

Review 4.  Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?

Authors:  Kimberly Janet Legault; Amaia Ugarte; Mark Andrew Crowther; Guillermo Ruiz-Irastorza
Journal:  Curr Rheumatol Rep       Date:  2016-05       Impact factor: 4.592

Review 5.  Antiplatelet drugs: clinical pharmacology and therapeutic use.

Authors:  A S Gallus
Journal:  Drugs       Date:  1979-12       Impact factor: 9.546

Review 6.  Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview.

Authors:  Roberta Gualtierotti; Marco Parisi; Francesca Ingegnoli
Journal:  Adv Ther       Date:  2018-03-20       Impact factor: 3.845

7.  Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials.

Authors:  Can Chen; Kunming Pan; Bingjie Wu; Xiaoye Li; Zhangzhang Chen; Qing Xu; Xiaoyu Li; Qianzhou Lv
Journal:  Eur J Clin Pharmacol       Date:  2020-08-11       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.